School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
NeuroMI (Milan Center for Neuroscience), Milan, Italy.
Methods Mol Biol. 2022;2547:95-140. doi: 10.1007/978-1-0716-2573-6_5.
Pharmacogenomics is a powerful tool to predict individual response to treatment, in order to personalize therapy, and it has been explored extensively in oncology practice. Not only efficacy on the malignant disease has been investigated but also the possibility to predict adverse effects due to drug administration. Chemotherapy-induced peripheral neurotoxicity (CIPN) is one of those. This potentially severe and long-lasting/permanent side effect of commonly administered anticancer drugs can severely impair quality of life (QoL) in a large cohort of long survival patients. So far, a pharmacogenomics-based approach in CIPN regard has been quite delusive, making a methodological improvement warranted in this field of interest: even the most refined genetic analysis cannot be effective if not applied correctly. Here we try to devise why it is so, suggesting how THE "bench-side" (pharmacogenomics) might benefit from and should cooperate with THE "bed-side" (clinimetrics), in order to make genetic profiling effective if applied to CIPN.
药物基因组学是一种强大的工具，可以预测个体对治疗的反应，从而实现个体化治疗，在肿瘤学实践中已经得到了广泛的探索。不仅研究了对恶性疾病的疗效，还研究了预测药物治疗不良反应的可能性。化疗引起的周围神经毒性（CIPN）就是其中之一。这种常见抗癌药物引起的潜在严重且持久/永久性副作用，可能会严重损害长期生存患者的生活质量（QoL）。到目前为止，基于药物基因组学的 CIPN 方法一直相当虚幻，因此有必要在这一感兴趣的领域进行方法学改进：即使是最精细的基因分析，如果应用不正确，也不会有效。在这里，我们试图解释为什么会这样，并提出“床边”（临床计量学）如何受益于和应该与“ bench-side”（药物基因组学）合作，以便在应用于 CIPN 时使基因分析有效。
